Profusa has signed an option agreement giving it the right to acquire commercial-stage diagnostics company G3 Vision Labs and its subsidiaries, which together generated estimated unaudited net revenues of approximately $111 million in 2025. The option is exercisable until 90 days after G3 delivers specified financial information, subject to conditions including Profusa raising at least $30 million in financing, refinancing or satisfying certain G3 indebtedness, and obtaining Nasdaq and stockholder approvals. As consideration for the option, Profusa issued 201,120 shares of common stock and 52,903.566 shares of a newly designated non-voting convertible preferred stock, with each preferred share convertible into 1,000 common shares upon stockholder approval. If the option is exercised, the combined company would operate as a public diagnostics company with national CLIA-certified laboratories serving addiction treatment, pain management, and behavioral health providers. The agreement does not constitute a change of control, and G3 stockholders retain the consideration if the option remains unexercised.
Profusa, Inc. Common StockProfusa signs option to acquire G3 Vision Labs, a diagnostics company with $111M revenue, potentially expanding its business.
G3 Vision Labs is the acquisition target, with Profusa issuing shares as consideration, indicating a deal that could benefit G3 stockholders.